Cereal sales may be in sharp decline, but that's not stopping General Mills from launching its first new breakfast cereal in 15 years.
Kashi is leading the way in promoting a new food label identifying farms transitioning from conventional to organic.
Jim Cramer explains what to watch ahead of the open, talks Kellogg and urges people to own these stocks "on the fundamentals."
CNBC's Jim Cramer explains why he is watching Kraft Heinz and how they are doing well.
U.S. stock index futures were higher Thursday morning, helped by gains in oil prices as concerns of a near-term supply shortage rose.
Markets are already fixated on Friday's jobs report amid concerns economic growth is just not strong enough.
Some 30 American companies were recognized for their efforts to boost diversity and inclusion.
Cereals are losing favor with time-poor, health-conscious consumers, who increasingly breakfast on snack bars and yogurt.
Jim Cramer on why giving up on Starbucks now could come back to haunt you.
A tight budget doesn't have to hold a business down. Entrepreneurs of three successful companies share how they made every dollar count.
Jim Cramer discussed the government's ability to revive this range of stocks.
Jim Cramer knows it is hard to buy the consumer staples trick. Here's the perfect time to make a move.
When it comes to buying behavior, a company's brand can overshadow its product, according to a survey released Tuesday.
Optimism is starting to seep through cracks in the dam of global water woes, according to Breakingviews.
General Mills reported lower-than-expected quarterly sales, hurt by a strong dollar and weaker sales in the United States.
A video has surfaced online of a man urinating on a factory assembly line, recorded in 2014.
Once thought to be unhealthy, butter is back. Demand is up and so are prices. What changed?
Data from Nielsen show that ready-to-eat cereal sales have been declining for several years.
Today's bell ringers are insurance holding company White Mountain Insurance Group and the company's CFO David Foy, at the NYSE, and clinical stage biopharmaceutical company Syndax Pharmaceuticals CEO Dr. Briggs W. Morrison, at the Nasdaq.
The recipe for avoiding too much volatility is playing it safe, Bruderman Brothers CEO Oliver Pursche told CNBC.